Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


  1. Value of flow cytometry for MRD-based relapse prediction in B-cell precursor ALL in a multicenter setting

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Clinical and genetic characteristics of children with acute lymphoblastic leukemia and Li-Fraumeni syndrome

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  3. Clinical impact of clonal hematopoiesis in patients with lymphoma undergoing ASCT: a national population-based cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Meletios Dimopoulos
  • Katja Weisel
  • Philippe Moreau
  • Larry D Anderson
  • Darrell White
  • Jesus San-Miguel
  • Pieter Sonneveld
  • Monika Engelhardt
  • Matthew Jenner
  • Alessandro Corso
  • Jan Dürig
  • Michel Pavic
  • Morten Salomo
  • Eva Casal
  • Shankar Srinivasan
  • Xin Yu
  • Tuong Vi Nguyen
  • Tsvetan Biyukov
  • Teresa Peluso
  • Paul Richardson
Vis graf over relationer

In the phase 3 OPTIMISMM trial, pomalidomide, bortezomib, and dexamethasone (PVd) demonstrated superior efficacy vs bortezomib and dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma previously treated with lenalidomide, including those refractory to lenalidomide. This analysis evaluated outcomes in patients at first relapse (N = 226) by lenalidomide-refractory status, prior bortezomib exposure, and prior stem cell transplant (SCT). Second-line PVd significantly improved PFS vs Vd in lenalidomide-refractory (17.8 vs 9.5 months; P = 0.0276) and lenalidomide-nonrefractory patients (22.0 vs 12.0 months; P = 0.0491), patients with prior bortezomib (17.8 vs 12.0 months; P = 0.0068), and patients with (22.0 vs 13.8 months; P = 0.0241) or without (16.5 vs 9.5 months; P = 0.0454) prior SCT. In patients without prior bortezomib, median PFS was 20.7 vs 9.5 months (P = 0.1055). Significant improvement in overall response rate was also observed with PVd vs Vd in lenalidomide-refractory (85.9% vs 50.8%; P < 0.001) and lenalidomide-nonrefractory (95.7% vs 60.0%; P < 0.001) patients, with similar results regardless of prior bortezomib or SCT. No new safety signals were observed. These data demonstrate the benefit of PVd at first relapse, including immediately after upfront lenalidomide treatment failure and other common first-line treatments.

Udgave nummer6
Sider (fra-til)1722-1731
Antal sider10
StatusUdgivet - jun. 2021

ID: 62110222